Recent Articles from Investor Brand Network

AST SpaceMobile (NASDAQ: ASTS) announced the pricing of $1.0 billion aggregate principal amount of 2.250% convertible senior notes due 2036 in a private offering to qualified institutional buyers under Rule 144A of the Securities Act of 1933. The notes carry an initial conversion price of approximately $116.30 per share, representing a roughly 20% premium to the company’s Feb. 11, 2026 closing price, and the offering is expected to close Feb. 17, 2026, subject to customary conditions. AST SpaceMobile also granted initial purchasers an option to buy up to an additional $150 million of notes, with proceeds expected to support global spectrum deployment, technology commercialization including artificial intelligence opportunities, government space initiatives, debt reduction and other general corporate purposes.

Gaxos.ai (NASDAQ: GXAI) announced that Malcolm B. Frost, a retired Major General in the United States Army, has joined the Drone and Robotics Advisory Council of America First Defense (“AFD”). Frost brings decades of leadership experience in modern warfare, military communications, and advanced defense technologies and will advise AFD on the development of AI-driven autonomous systems, drone defense technologies, and next-generation robotic platforms. The advisory council is composed of military leaders, technologists, and national security experts who guide the company’s efforts to develop solutions addressing the rapidly expanding global market for counter-drone and autonomous defense systems.

Oragenics (NYSE American: OGEN) announced it has received final Human Research Ethics Committee approval in Australia to begin its Phase IIa clinical trial evaluating ONP-002, its lead intranasal neurosteroid drug candidate for the treatment of concussion, also known as mild traumatic brain injury. With all regulatory approvals secured, the company has initiated clinical site onboarding at three locations in Australia, led by Bayside Health (Alfred Health), and expects to dose the first patient before the end of March. The randomized, placebo-controlled study will enroll 40 patients to evaluate safety, tolerability and feasibility of ONP-002, with data expected before year-end 2026 as the company prepares for a future investigational new drug application to support additional U.S. clinical trials.

The strongest argument for transitioning to renewable energy may no longer be combating climate change. Across conflict zones and volatile energy markets, a more urgent case for ditching fossil fuels is being made in real time: national security .

For years, most established companies kept their distance from crypto payments. That stance is gradually shifting . As businesses reassess how they handle transactions, many are focusing on factors such as cost efficiency, convenience, security, and speed.

Stocks of U.S. banks struggled in February 2026, performing worse than the broader stock market. New data from market analysts shows that the banking sector faced a difficult month as investors reacted to economic uncertainty, company deals, and changing expectations in the financial industry.

Many countries in Europe, including France, Greece, Spain, Denmark, Britain, Germany, and many more, are either considering investigating social media platforms over harmful content or considering the imposition of bans on social media access by minors. Why, you may be wondering, is this happening at this point in time ?

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The partnership will combine HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from three non-coplanar dimensions, with Mount Sinai’s clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring. By leveraging longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai’s clinical data resources, the collaboration aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical indications and enable broader applications in preventive cardiology, chronic disease management and remote patient monitoring.

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising.

Renewal Fuels (OTC: RNWF), doing business as American Fusion Inc., was featured in the latest episode of The Stock2Me Podcast released by IBN, highlighting Kepler Fusion Technologies, a wholly owned subsidiary developing the Texatron(TM) aneutronic fusion platform. During the episode, Kepler Fusion CEO Brent Nelson discussed the company’s progress toward deploying a fully operational 100-megawatt fusion reactor, including a 5-megawatt pre-production model currently under development, and outlined its power-as-a-service strategy targeting data centers and industrial customers. Nelson also detailed the company’s economic model and scaling plans, noting potential pricing of approximately 6.25 cents per kilowatt-hour and a long-term goal of delivering about one gigawatt of power by 2028 as the company works to commercialize fusion-based energy solutions.

Tonix Pharmaceuticals (NASDAQ: TNXP) announced two oral presentations on TONMYA(TM), investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. Post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies highlighted rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia, including statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15 years, was generally well tolerated, with mild and transient oral cavity reactions reported as the most common adverse events.

Frontieras North America, an energy and environmental technology company commercializing its patented FASForm(TM) Solid Carbon Fractionation process, announced it will host a groundbreaking ceremony on April 2, 2026, for its first commercial facility in Mason County, West Virginia. The estimated $850 million industrial project is expected to create approximately 300 full-time jobs with wages averaging three times the area’s average income, along with about 2,000 construction jobs during the build phase. The ceremony, scheduled for 11:30 a.m. ET, will include remarks from company leadership and federal and state officials, followed by a ceremonial groundbreaking. The company’s FASForm(TM) technology is designed to convert coal and other hydrocarbons into fuels and products such as liquid fuels, hydrogen, fertilizer inputs and industrial carbon through a closed-loop process that captures and repurposes byproducts.

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet’s Disease. The designation represents the first step toward potential inclusion in the U.K.’s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier. The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

This article has been disseminated on behalf of McEwen Inc. and may include paid advertising.

Uranium Energy (NYSE American: UEC) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended Jan. 31, 2026, highlighting progress across its U.S. in-situ recovery (“ISR”) uranium operations and balance sheet strength. During the quarter, the company completed construction of the Burke Hollow ISR uranium mine, expanded production capacity in Wyoming and South Texas pending final regulatory approvals and advanced feasibility, siting and licensing work for United States Uranium Refining & Conversion Corp. UEC also reported selling uranium at prices more than 25% above the quarterly average while maintaining $818 million in liquid assets and no debt at quarter end, positioning the company to scale production and support development of a vertically integrated U.S. nuclear fuel supply chain.

Lawmakers in Washington State have approved a proposal that would allow patients with terminal illnesses to use medical marijuana in certain healthcare facilities, including hospices, hospitals, and nursing homes. The measure now awaits action from Governor Bob Ferguson.

Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and commercialization of fusion energy technologies, is working to advance its Texatron(TM) aneutronic fusion system, while simultaneously strengthening governance, engineering leadership and regulatory positioning.

For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward. In that context, Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need, announced that it has received a positive opinion from the EMA’s Committee for Orphan Medicinal Products for its pipeline product dusquetide in the treatment of Behcet’s disease.

Ongoing digital monitoring could be about to solve one of modern medicine’s most frustrating access problems. Life-extending cancer immunotherapies exist and there are numerous patients who could benefit from such therapies, but a mandatory hospital stay requirement currently makes access to immunotherapy nigh impossible for rural and underserved patients.

Financial services are at a tipping point . Artificial intelligence and modernization are no longer separate trends; they are now deeply connected, reshaping how banks and financial institutions operate, compete, and earn trust.

On Thursday, the prices of gold and silver retreated sharply, putting the precious metals on course to end the week on a low. Several factors could be behind this price movement as the usual suspects, such as a surging USD and rising Treasury yields don’t sufficiently explain this price correction.

Octane announced that the Octane Neuro Tech Forum 2026 will take place March 26-27, 2026, at VEA Newport Beach, A Marriott Resort & Spa in Newport Beach, California, bringing together industry leaders, clinicians, investors and entrepreneurs to advance innovation in neurotechnology. The event, part of Octane’s Innovation Event Series, will feature keynote speaker Dr. Adnan Siddiqui, CEO and CMO of the Jacobs Institute, along with more than 30 expert speakers addressing emerging neurotech technologies, digital health innovation, brain-computer interfaces and the evolving investment landscape. The forum will include innovation panels, investor-focused sessions, company presentations and networking opportunities designed to foster partnerships and accelerate development of next-generation neurotechnology solutions.

This article has been disseminated on behalf of Nicola Mining Inc. and may include paid advertising.

HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring clinically meaningful ECG data out of traditional healthcare facilities and into more accessible, patient-centered settings.

Wearable Devices (NASDAQ: WLDS), a technology growth company specializing in artificial intelligence-powered touchless sensing wearables, announced it will implement a one-for-three reverse split of its ordinary shares and tradable warrants, effective when trading begins on a split-adjusted basis on March 11, 2026. The action is intended to increase the company’s per-share trading price to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Following the reverse split, the number of issued and outstanding ordinary shares will be reduced from 10,593,227 to approximately 3,531,076, while publicly held warrants will decrease from 98,589 to about 32,863, with trading to continue under the existing ticker symbols “WLDS” and “WLDSW.” The move was approved by shareholders at a Feb. 19, 2026 special meeting, and the company expects the reverse split to maintain proportional ownership among shareholders, subject to rounding adjustments for fractional shares.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging. In addition, Eno, Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30, where the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

This article has been disseminated on behalf of G Mining Ventures Corp. and may include paid advertising.

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic in Palm Beach, Florida, focused on treating depression and post-traumatic stress disorder through an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy and physician-led psychotherapy. The facility expands HOPE’s growing network of clinics and builds on a nationwide partnership with neurocare AG to bring non-invasive neuroplastic therapies to patients. Peer-reviewed publications cited by the company report an 87% clinical response rate in treatment-resistant depression using short-term treatment protocols, while pilot programs incorporating hyperbaric oxygen therapy have shown a 90% return-to-function rate among patients with depression and PTSD.

Frontieras North America is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

This article has been disseminated on behalf of Silvercorp Metals and may include paid advertising.

A proposal now before the Georgia legislature could significantly change how law enforcement officers handle traffic stops and searches, focusing on the long-debated practice of using the odor of cannabis as grounds for action.

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move.

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its positioning opposite of many capitalization structures in the landscape of over-the-counter (“OTC”) markets, with its management team owning over 47% of the company’s shares. “This high level of insider ownership is significant, as it shows the leadership team strongly believes in the company and has financial outcomes tied closely to the stock’s performance,” reads the publication. “As a result, this greatly reduces the risk that management benefits while investors don’t, as management is financially aligned with outside investors… This high insider ownership also ensures the company is intensely focused on creating shareholder value, as even a tiny swing in the stock price could have massive financial implications for the team… and also points to the company funding operations through cash flow, and not toxic financing.”

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

Artificial intelligence has triggered a global race for computing capacity, but a serious bottleneck is beginning to emerge: electricity . For companies building and operating AI infrastructure, access to reliable power is becoming as critical as access to advanced semiconductors. That shift is creating opportunities for GridAI Technologies (NASDAQ: GRDX), a technology company focused on intelligent energy orchestration.

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTC: SPAIF) and may include paid advertising.

Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to the immune system. Researchers are increasingly focused on strategies that make tumors more visible and susceptible to immune attack, and LIXTE Biotechnology Holdings (NASDAQ: LIXT) is developing a compound designed to contribute to that effort. Its lead candidate, LB-100, targets a cellular enzyme involved in tumor biology and immune regulation, with the goal of enhancing responsiveness to existing cancer therapies.

This article has been disseminated on behalf of Ucore Rare Metals, Inc. and may include paid advertising.

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(TM). Published in Clinical Pharmacology in Drug Development , the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA’s proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism. The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to the long-acting metabolite norcyclobenzaprine, supporting durable analgesic benefits with improved tolerability.

The start of this year saw the price of copper surge significantly, reaching an all-time high of $14,527.50 per metric ton on the London Metal Exchange. While the price has eased slightly since then, it still remains at about $13,000. This reflects a combination of constrained global supply, accelerating demand, and mounting geopolitical uncertainties.

A technical standoff brewing inside electric vehicle charging infrastructure is quietly blocking one of the most promising energy opportunities available to American and European drivers alike. Until the war between AC and DC current gets settled, vehicle-to-grid technology (V2G) will remain a compelling idea that may never quite reach the people it could benefit the most.

Oregon State University researchers have engineered a new nanomaterial from iron that kills cancer cells inside tumors and leaves normal cells unaffected. This new nanomaterial works by triggering two chemical reactions inside tumors and the cancer cells die off as a result of these reactions.

The global race to develop AI is no longer moving along a single track, according to a new study. Instead, it is dividing into three blocs led by China, the EU, and the U.S., with each bloc guided by its own political priorities, governance, and economic model.

Beeline Holdings (NASDAQ: BLNE), a rapidly growing digital mortgage platform company redefining the path to homeownership, operates at the intersection of mortgage lending, title services, and financial technology, offering a digital-first alternative to a process that has historically been paper-heavy and time-consuming. Through its wholly owned subsidiary, Beeline Loans Inc., the company provides mortgage products designed to be originated, processed, and closed largely online.

VolitionRx (NYSE American: VNRX) announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan, enabling full automation in central laboratories through the IDS i10 automated analyzer platform. The company said the transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows, with more than 1,700 veterinary hospitals in Japan already registered to use the test. Volition highlighted Japan’s approximately seven million pet dogs and noted the automated platform aligns with the same system used for its human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy.

Offshore wind developers and energy companies are lobbying to put renewables at the heart of Europe’s forthcoming Ocean Act, warning that without strong protections written into the legislation, competing maritime interests could slow one of the continent’s most critical energy buildouts. With the Act’s publication expected late in 2026, the window to influence the Act’s direction is narrowing fast.

The cryptocurrency market has continued to slide in 2026, adding to losses that began after the sharp downturn last October. Despite the pullback, asset manager Grayscale Investments says the current environment may present an opening for investors with a long-term outlook.

Many companies are racing to put self-driving cars on roads in major markets around the world, such as U.S. cities, China and Europe. These companies need to pick some valuable lessons from military drones that have come a long way from the early days when drones were in the trial and error phase. We discuss some of those key lessons that firms operating robotaxis need to learn and implement.

A new study has raised serious concerns about how accurately electric vehicle (EV) owners are being billed when they use public charging stations. As more drivers switch from gasoline and diesel cars to electric vehicles, public trust in charging infrastructure is becoming increasingly important. However, recent findings suggest that many EV drivers may not be getting exactly what they pay for.

The legal marijuana sector has long operated under a patchwork of rules and shifting policies. Now, a new round of trade measures under President Donald Trump is adding fresh strain to an already complex marketplace.

Forward Industries (NASDAQ: FWDI), a rapidly growing Solana treasury company, recently shared an update about its total Solana (SOL) holdings. “In the update, the company announced that it now holds over 6.97 million SOL. The company also announced that FWDI’s validator infrastructure has generated 6.73% gross APY before fees, outperforming many of the top peer validators,” reads a related article. “The update states that nearly all of the company’s SOL holdings are staked, and it continues to maintain sufficient operating capital, and has zero corporate debt. It also highlighted a few of the company’s recent operational moves, such as the fact that FWDI began testing a PropAMM on Solana.”

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

OptimumBank Holdings (NYSE American: OPHC), a community and business bank serving Florida, entered 2026 on the heels of a broad reworking of its capital structure, a process management describes as laying a clearer foundation for the company’s next phase of growth. “The initiative, detailed in a Jan. 5 announcement , reflects coordinated actions by OptimumBank’s largest institutional investor and key insiders, with an emphasis on transparency, alignment, and long-term flexibility,” reads a recent article. “The Fort Lauderdale-based holding company said the changes were undertaken to modernize legacy equity arrangements and to better reflect the scale the institution has reached. OptimumBank Holdings, Inc. surpassed $1.1 billion in assets last year, a milestone that Chairman Moishe Gubin has cited as a natural point to reassess how capital is structured and presented to the market.”

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

Disseminated on behalf of MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) and may include paid advertising.

Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

Massimo Group (NASDAQ: MAMO) a manufacturer and distributor of powersports vehicles, utility vehicles and related equipment, announced that a long-standing national rural lifestyle retail partner has authorized one of the company’s core products for placement across 1,000 U.S. retail locations. The initial rollout will include approximately 2,400 units supported through both physical retail stores and the retailer’s online platform, establishing an integrated omnichannel sales approach and creating a scalable pathway for potential expansion across the retailer’s roughly 2,200 U.S. locations, subject to performance and ongoing evaluation.

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising.

Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix (NASDAQ: SNGX) exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced it will implement a 1-for-8 reverse stock split of its common stock effective at the opening of trading on March 9, 2026, while continuing to trade on the Nasdaq Capital Market under the symbol ADTX. The reverse split, approved by stockholders at a Feb. 13, 2026 special meeting and finalized by the company’s board of directors, is intended primarily to help the company regain compliance with Nasdaq’s minimum bid price requirement.

Frontieras North America, an energy and environmental technology company commercializing its patented FASForm(TM) Solid Carbon Fractionation process, today announced the appointment of Nora Shepard as vice president of communications as the company advances commercialization of its first FASForm(TM) facility in Mason County, West Virginia and expands engagement with institutional investors, strategic partners and policymakers. In her new role, Shepard will oversee corporate communications, investor messaging, brand strategy and executive positioning, supporting Frontieras’ efforts to align operational execution with capital markets strategy as it progresses toward deployment of its flagship facility designed to process 7,500 tons of coal per day.

Anthropic’s AI assistant Claude surged to the top of Apple’s list of most downloaded free apps in the U.S. on Saturday evening, just one day after the Trump administration moved to prevent federal agencies from adopting the company’s technology.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the enrollment of the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marking a key step toward generating the clinical data needed to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack detection.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, will host a conference call at 4:30 p.m. Eastern time on March 12, 2026, to discuss its financial results for the fourth quarter and full year ended Dec. 31, 2025, and provide updates on key strategic growth initiatives, including the limited commercial launch and progress on its 12-lead ECG extended wear patch. A press release detailing the results will be issued prior to the call.

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

Trump’s assault on Iran has produced an outcome he almost certainly did not plan for: a powerful, real-world advertisement for ditching fossil fuels. With energy markets destabilized and drivers across the world bracing for another squeeze at the pump, the economic case for clean energy has rarely felt more urgent or better supported.

As many companies work to put autonomous vehicles (self-driving cars) on roads, scientists are working to find ways to increase the safety of these vehicles not just for the passengers they carry but also for those in the environment, such as cyclists and pedestrians. A team of researchers has come up with a concept involving installing radar sensors on roadsides to augment the onboard sensors in autonomous vehicles.